13 Best Get Rich Fast Stocks to Buy Right Now

Page 6 of 12

7. Absci Corporation (NASDAQ:ABSI)

Upside Potential as of December 24, 2025: 150.70%

Number of Hedge Fund Holders: 18

Share Price as of December 24, 2025: $3.59

As of December 24, Absci Corporation (NASDAQ:ABSI) is a consensus buy among all nine analysts covering the stock. The median price target of $9 translates to an upside potential of 150.70%.

On December 17, H.C. Wainwright reaffirmed the ‘Buy’ rating on Absci Corporation (NASDAQ:ABSI), while raising the price target to $8 from $7. The price target revision, reflecting an upside potential of 125%, follows the firm’s incorporation of ABS-201 into the company’s model. This comes after the company’s investor event in which it discussed the androgenetic alopecia program for ABS-201.

According to the research note, ABS-201 exhibits the potential to expand the proportion of hair follicles in the growth phase relative to the resting phase, a stage during which hair shedding occurs. H.C. Wainwright’s confidence in the ABS-201 program is driven by the strength of the preclinical evidence.

Earlier, on December 11, Absci Corporation (NASDAQ:ABSI) disclosed new preclinical data for its AI-designed antibody, ABS-201, indicating that the drug may effectively stimulate hair growth in human scalp tissue samples. Presented during a Key Opinion Leader seminar, the data showed that ABS-201 targets the prolactin receptor (PRLR) to stimulate hair growth by supporting not only stem cell preservation but also prolonging the active growth phase of hair follicles.

Absci Corporation (NASDAQ:ABSI) is a Washington-based, data-first, generative AI drug-creation company. Founded in 2011, the company integrates AI with scalable wet lab technologies to develop unique antibody therapeutics.

Page 6 of 12